Oxygen Biotherapeutics Issued U.S. Patent for Dermatologic Indications

  Oxygen Biotherapeutics Issued U.S. Patent for Dermatologic Indications

                      Marks Company's 9th Patent Issued

Business Wire

MORRISVILLE, N.C. -- September 10, 2013

Oxygen Biotherapeutics, Inc., (“OBI”) (NASDAQ: OXBT) a developer of
oxygen-carrying therapeutics, today announced that the United States Patent
and Trademark Office has issued the Company patent#8,513,309, titled,
“Perfluorocarbons for use in Treating Pruritus.” This patent addresses methods
for treating pruritus (itching), a sensation that a patient instinctually
attempts to relieve by rubbing or scratching.

The newly issued patent addresses part of the global dermatological drugs
market, which is projected to reach $24.4 billion by 2015, according to market
research firm Visiongain. The Company is currently evaluating
commercialization strategies, which may include out-licensing, for
prescription dermatologic indications of PFC-based products for conditions
including allergic contact dermatitis, psoriasis and acne.

Among several beneficial properties, the Company’s platform technology of
proprietary perfluorocarbons (PFCs) carry 4 times more oxygen than red blood
cells (RBCs), have 20 times higher oxygen solubility than water, and form
stable emulsions 35 - 40 times smaller than RBCs.

In May of 2012, Oxygen Biotherapeutics completed a clinical study in which its
proprietary PFC-based emulsion showed efficacy in relieving histamine-induced
pruritus. Efficacy in treating pruritus was assessed, as reported by each
subject using a Visual Analogue Scale, a validated instrument used to evaluate
itch in clinical studies. The randomized, double-blind, placebo-controlled
study which included 30 healthy male and female volunteers aged 18-65 showed
that there was a profound drop in itch sensation when the Company’s PFC-based
topical treatment was applied.

"This latest patent builds upon our family of patents that address
dermatologic conditions. While our focus is the development of PFCs for
critical indications, we seek to unlock the value of our IP through
out-licensing non-core indications including those in dermatology," stated
Michael Jebsen, Interim CEO, President and Chief Financial Officer.

Oxygen Biotherapeutics now owns or in-licenses 9 issued patents for medical
and dermatological conditions with an average remaining life of approximately
18 years. Oxygen Biotherapeutics relies on a combination of use, method,
therapeutic, delivery and composition patents, patent applications, trade
secrets, and proprietary know-how in order to protect its medical products.
The Company is also expanding its IP portfolio by exploring new high-potential
therapeutic applications through third-party research collaborations.

“Perfluorocarbons for use in Treating Pruritus” Patent Abstract:

The subject application provides a method of treating pruritus comprising
administering to the skin of a subject afflicted with pruritus an amount of
perfluorocarbon effective to treat the pruritus. The subject application
provides a method of alleviating a symptom of psoriasis comprising
administering to the skin of a subject afflicted with psoriasis an amount of a
perfluorocarbon effective to alleviate the symptom of psoriasis. The subject
application also provides a perfluorocarbon composition for use in treating a
subject afflicted with pruritus or psoriasis. The subject application further
provides a pharmaceutical composition comprising an amount of perfluorocarbon
for use in treating pruritus or psoriasis.

About Oxygen Biotherapeutics, Inc.

Oxygen Biotherapeutics, Inc. is developing medical products that efficiently
deliver oxygen to tissues in the body. The company has developed a proprietary
perfluorocarbon (PFC) therapeutic oxygen carrier called Oxycyte^®that is
currently in clinical and preclinical studies for intravenous delivery for
indications such as traumatic brain injury, decompression sickness and stroke.
The company is also developing PFC-based creams and gels for topical delivery
to the skin for dermatologic conditions and potentially wound care. In
addition, the Company has commercialized its Dermacyte^®line of skin care
cosmetics for the anti-aging market. Dermacyte is now out-licensed to Valor
Cosmetics of Switzerland.

Caution Regarding Forward-Looking Statements

This news release contains certain forward-looking statements by the company
that involve risks and uncertainties and reflect the company’s judgment as of
the date of this release. The forward-looking statements are subject to a
number of risks and uncertainties, delays in new product introductions and
customer acceptance of these new products, and other risks and uncertainties
as described in our filings with the Securities and Exchange Commission,
including our annual report on Form 10-K filed on June 26, 2013, as well as
other filings with the SEC. The company disclaims any intent or obligation to
update these forward-looking statements beyond the date of this release. This
caution is made under the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995.

Contact:

Oxygen Biotherapeutics Investor and Media Relations
Robert Haag, 866-976-IRTH (4784)
Managing Director
IRTH Communications
oxbt@irthcommunications.com